Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Danielle E Bolland"'
Autor:
Kari E Hacker, Danielle E Bolland, Lijun Tan, Anjan K Saha, Yashar S Niknafs, David M Markovitz, Karen McLean
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 12, Pp 1209-1218 (2018)
DNA damage repair alterations play a critical role in ovarian cancer tumorigenesis. Mechanistic drivers of the DNA damage response consequently present opportunities for therapeutic targeting. The chromatin-binding DEK oncoprotein functions in DNA do
Externí odkaz:
https://doaj.org/article/32897ee09bdf49fea7db06aafbb9c0bc
Autor:
Madhur Shetty, Danielle E. Bolland, Joshua Morrell, Bryon D. Grove, James D. Foster, Roxanne A. Vaughan
Publikováno v:
Current Research in Physiology, Vol 6, Iss , Pp 100106- (2023)
The primary regulator of dopamine availability in the brain is the dopamine transporter (DAT), a plasma membrane protein that drives reuptake of released dopamine from the extracellular space into the presynaptic neuron. DAT activity is regulated by
Externí odkaz:
https://doaj.org/article/2cd3ce10da6d4b5ab18d57d3cadadfb7
Autor:
Lijun Tan, Katelyn Tondo-Steele, Caroline Foster, Carrie McIlwain, Danielle E. Bolland, Howard C. Crawford, Andrew Sciallis, Karen McLean
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4675
Antiestrogen therapy (AET) is an alternative to cytotoxic chemotherapy for recurrent ovarian cancer, yet the often short duration of response suggests mechanisms of resistance. We previously demonstrated that tumor microenvironment interleukin-6/leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a692ed87bb9eed9989e41c1312e2db
https://pubmed.ncbi.nlm.nih.gov/36230597
https://pubmed.ncbi.nlm.nih.gov/36230597
Autor:
Daniel J. Stanislowski, Amy E. Moritz, James D. Foster, Danielle E. Bolland, Roxanne A. Vaughan
Publikováno v:
ACS Chem Neurosci
The dopamine transporter (DAT) is a plasma membrane protein that mediates the reuptake of extracellular dopamine (DA) and controls the spatiotemporal dynamics of dopaminergic neurotransmission. The transporter is subject to fine control that tailors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd05460aad249c5eb1065653be4315cc
https://doi.org/10.1021/acschemneuro.8b00558
https://doi.org/10.1021/acschemneuro.8b00558
Autor:
David M. Markovitz, Anjan K. Saha, Yashar S. Niknafs, Lijun Tan, Karen McLean, Danielle E. Bolland, Kari E. Hacker
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 12, Pp 1209-1218 (2018)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
DNA damage repair alterations play a critical role in ovarian cancer tumorigenesis. Mechanistic drivers of the DNA damage response consequently present opportunities for therapeutic targeting. The chromatin-binding DEK oncoprotein functions in DNA do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b560c61371e8167e90cc6b5fb95361e
http://www.sciencedirect.com/science/article/pii/S1476558618304391
http://www.sciencedirect.com/science/article/pii/S1476558618304391
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth
Autor:
Lijun Tan, Moshe Talpaz, Nouri Neamati, Danielle E. Bolland, Ronald J. Buckanovich, Karen McLean, Luke F. Peterson, Lan G. Coffman
Publikováno v:
Oncogene
Ovarian carcinoma-associated mesenchymal stem cells (CA-MSC) produce not only high levels of IL6 but also the related cytokine leukemia inhibitory factor (LIF). Interleukin 6 (IL6) mediated activation of STAT3 is implicated as a critical therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5fe08f4afe9d0220f67084ec2bb26e3
https://doi.org/10.1038/s41388-018-0523-6
https://doi.org/10.1038/s41388-018-0523-6
Autor:
James D. Foster, Danielle E. Bolland, Joseph J. Provost, Mark Wallert, Moriah J. Hovde, Roxanne A. Vaughan
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18a8ba401a617e01a8e17867ad466178
https://doi.org/10.1096/fasebj.2019.33.1_supplement.632.8
https://doi.org/10.1096/fasebj.2019.33.1_supplement.632.8
Autor:
Ishfaq Ahmed, Sabah Akhtar, Atiah H. Almalki, Hamda A. Al-Naemi, Batool Al-Qambar, Hashem O. Alsaab, Yusuf S. Althobaiti, Rami Alzhrani, C Annageldiyev, Asfar S. Azmi, Surinder K. Batra, Meghan Bialt-DeCelie, Stephanie J. Blocker, Danielle E. Bolland, Mahmoud Chaker, Hui-Hua Chang, Minsig Choi, D.C. Claxton, Guido Eibl, Hassan Fadel, Koelina Ganguly, Heather L. Gardner, John D. Haley, Mohammad Haris, Arun K. Iyer, Mandana Kamgar, Sukhwinder Kaur, Abdul Q. Khan, Rehan Khan, Neil Klinger, Bradley Kolb, Shilpa Kuttikrishnan, Yiwei Li, Priya Londhe, Cheryl A. London, S.V. Madhunapantula, Adhip P.N. Majumdar, Ashiq Masood, Christopher I. McHugh, Karen McLean, Sandeep Mittal, Ramzi M. Mohammad, Fatima Mraiche, Irfana Muqbil, T.N. Patel, Sam G. Pappas, Philip A. Philip, Kirti S. Prabhu, Khalid Rashid, Syed Shadab Raza, Samaresh Sau, Muralitharan Shanmugakonar, A Sharma, Anthony F. Shields, Surendra Kumar Shukla, Pankaj Kumar Singh, Kodappully S. Siveen, Anteneh Tesfaye, Shahab Uddin, Kay Uwe-Wagner, Nerissa Viola-Villegas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72fd176301d012f7681b43661b0cd107
https://doi.org/10.1016/b978-0-12-814704-7.09992-x
https://doi.org/10.1016/b978-0-12-814704-7.09992-x
Autor:
Karen McLean, Danielle E. Bolland
The overall poor clinical outcome for women with ovarian cancer necessitates accurate tumor model systems that can yield preclinical advances for translation to new patient-centered treatment strategies. Our preclinical knowledge of ovarian cancer is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cfd6f078552c08b0c7a2f4c72d715f2
https://doi.org/10.1016/b978-0-12-814704-7.00002-7
https://doi.org/10.1016/b978-0-12-814704-7.00002-7
Autor:
Karen McLean, Yuning Hao, Lijun Tan, Yee Sun Tan, Yu Lei, Yuying Xie, Jake J. Reske, Danielle E. Bolland, Ronald L. Chandler
Publikováno v:
Clinical Cancer Research. 26:B05-B05
Purpose: Current immunotherapy response rates in high-grade serous carcinoma (HGSC) of the ovary, fallopian tube, and peritoneum are 10-15%. We sought to determine if decreasing levels of the DNA damage repair protein DEK or inhibiting its downstream
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd9c304d0586cfba03ceef2ebd6b8718
https://doi.org/10.1158/1557-3265.ovca19-b05
https://doi.org/10.1158/1557-3265.ovca19-b05